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FDG/PET in CLL today -----------------------------------------------------------------------------------------------------
Stefano Molica confirmation, PET/CT is useful to identify sites in which a tissue biopsy is more likely to be diagnostically informative. there is a continuous spectrum of lesions from typical to fully transformed cases should not be surprising and fits with our current understanding of CLL pathogenesis. 10 With this in mind, the different FDG/PET patterns observed in CLL are most likely a mere reflection of different, but unfrozen, phases of CLL biology.
Where do we stand today in using FDG/ PET to benefit CLL patients? FDG/PET is important for detecting disease transformation, a not infrequent phenomenon that in the case of RS can be estimated to occur in around 10% of patients. Disease transformation, which is frequently overlooked, has an extremely poor prognosis and requires aggressive therapy. 5, 9 There are some clinical hints to suspect disease transformation, including the development of general symptoms, enlarging lymphadenopathy, and increasing LDH. A positive FDG/PET not only supports the possibility of transformation but points to the site where a biopsy is more likely to be informative. On the other hand, the available studies do not justify using FDG/PET routinely in the prognostic evaluation or response to therapy assessment in patients with untransformed CLL. The MDACC group study sets the stage for other prospective studies to further elucidate the role of FDG/PET in the management of CLL. Meanwhile, outside of clinical trials, FDG/PET has an important role in supporting the possibility of disease transformation and guiding tissue biopsy.
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